Sign Up for Alerts
Sign up to receive receive industry-specific emails from our legal team.
Sign Up for Alerts
We provide tailored, industry-specific legal updates to our clients and other friends of the firm.
Areas of Interest
November 19th, 2025
Copyright Guide or Policy Change? Project Divides IP Attys
Ms. Charlesworth criticized the initiative as advancing a “revisionist theory” that could weaken copyright protections. She was among nearly two dozen advisers who resigned from the project, signaling deep concerns about its direction.
The article highlights a broader debate within the IP community: whether the restatement simply clarifies existing law or attempts to reshape policy in favor of users. Ms. Charlesworth’s perspective emphasizes the stakes for rights holders as courts and practitioners consider how much influence the restatement may carry. Read the Law360 article about the copyright restatement project here.
Other Quoted
Climate Diaries Cannes Lions 2026
Jeffrey A. Greenbaum is featured in the 51toCarbonZero article, Climate Diaries Cannes Lions 2026, which features eleven interviews with senior leaders from across the media and advertising industry conducted at the Cannes Lions International Festival of Creativity. Read more.
August 5 2026
‘I have been hunted down by HR reps, lawyers, and comms people:’ Developers discuss the pain and prevalence of side work clauses
Wendy Stryker was quoted in a Game Developer article discussing "side work clauses," also known as "moonlighting clauses," in video game industry employment contracts. Read more.
July 30 2026
Experts: Ending Adequate Provision Would Shut Down Prescription Drug Ads
Jeffrey A. Greenbaum was quoted in the Regulatory Affairs Professionals Society (RAPS) article, "Experts: Ending Adequate Provision Would Shut Down Prescription Drug Ads." The article discusses the FDA's proposal to eliminate the "adequate provision" requirement in direct-to-consumer (DTC) prescription drug advertising, a change that experts say could effectively result in a de facto ban on prescription drug advertisements. Read more.
July 21 2026
